Effects of anagliptin/metformin combination tablets: a retrospective observational study

Effects of anagliptin / metformin hydrochloride combination tablets in patients with type 2 diabetes: a retrospective observational study - Effects of anagliptin / metformin hydrochloride combination tablets in patients with type 2 diabetes: a retrospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041979

Enrollment

100

Registered

2020-10-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes 2. Patients who started receiving of anagliptin / metformin hydrochloride combination tablets from November 21st, 2018 to May 31st, 2020 (data collection period) and continued for more than 12 weeks

Exclusion criteria

Exclusion criteria: 1. Patients who received antidiabetic drugs for less than 8 weeks before switch to anagliptin / metformin hydrochloride combination tablets 2. Patients who denied the use of clinical medical records to the study

Design outcomes

Primary

Measure	Time frame
Change in HbA1c	—

Secondary

Measure	Time frame
1.Change in LDL-C 2.Change in HDL-C 3.Change in eGFR 4.Change in body weight, BMI and body composition 5.Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactMasahiro Fukuda

Fukuda Clinic Internal Medicine

fukuda@drmog.jp06-6398-0203

Outcome results